- Insider Monkey
20 Most Valuable Belgian Companies in 2024
In this article, we will be looking at the 20 most valuable Belgian companies in 2024. If you wish to skip our detailed analysis, you can move directly to the 5 Most Valuable Belgian Companies in 2024. Economy of Belgium: An Analysis Belgium has a small and open economy which recorded a GDP worth $627.51 […]
- Benzinga
FDA Approves Rystiggo: The Only Treatment for Two Most Common Subtypes of Generalized Myasthenia Gravis in Adults
The FDA approved UCB SA's (OTC: UCBJF) (OTC: UCBJY) Rystiggo (rozanolixizumab-noli) for generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AchR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive. The company says Rystiggo is the only FDA-approved treatment in adults for anti-AChR and anti-MuSK antibody-positive gMG, the two most common subtypes of gMG. The FDA approval is supported by safety and efficacy data from the pivotal Phase 3 Mycarin
